STSA-1005 injection, a wholly-owned subsidiary of Shutaishen, obtained clinical trial approval from the U.S. FDA

On September 7, Stadson BioPharma Inc.
announced that its wholly-owned subsidiary, Staidson BioPharma Inc.
(California Biotech Co.
, Ltd.
) (hereinafter referred to as “Sureth California” or the “Company”) has received American Food and Drugs.
The FDA's notification email agrees that STSA-1005 injection will be used for the treatment of severe COVID-19 in clinical trials for the treatment of severe COVID-19 indications
.

Granulocyte-macrophage colony stimulating factor (GM-CSF) is a hematopoietic growth factor that stimulates the survival of granulocytes and monocytes by binding to the GM-CSF receptor (GM-CSFR or GMR) on the cell membrane.
Proliferation and activation, GMR is composed of specific ligand binding to the α chain (GM-CSFRα/GMRα) and signal transduction β chain (GM-CSFRβ/GMRβ)
.

STSA-1005 injection is independently developed by the company's wholly-owned subsidiary Stadson BioPharma Inc.

This new drug clinical trial license is the first clinical trial license for STSA-1005 injection in the world